Cargando…

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

OBJECTIVE: The objective of this study was to explore whether soluble programmed death ligand 1 (sPD-L1) is a potential prognostic biomarker in patients with non-small cell lung cancer (NSCLC). METHODS: A comprehensive search of electronic databases was carried out. Original studies with inclusion o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Guixiang, Zhao, Zhihong, Qian, Yuting, Ling, Xiean, Chen, Shanyi, Li, Xianming, Kong, Feng-Ming (Spring)
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732757/ https://www.ncbi.nlm.nih.gov/pubmed/35004295 http://dx.doi.org/10.3389/fonc.2021.774131

Ejemplares similares

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus
por: Qian, Yuting, et al.
Publicado: (2022)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review
por: Liao, Guixiang, et al.
Publicado: (2021)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
por: Liu, Xiaofeng, et al.
Publicado: (2019)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
por: Shi, Tao, et al.
Publicado: (2021)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma
por: Golijanin, Borivoj, et al.
Publicado: (2021)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis
por: Cui, Hongxia, et al.
Publicado: (2021)

Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2020)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients
por: Wang, Feng, et al.
Publicado: (2020)

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
por: Li, Zaishang, et al.
Publicado: (2021)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
por: Khan, Muhammad, et al.
Publicado: (2021)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in “High-Risk” Patients Following Radical Cystectomy: A Retrospective Cohort Study
por: Lee, Chung Un, et al.
Publicado: (2021)

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
por: Herbst, Roy, et al.
Publicado: (2021)

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
por: Park, Hyunkyung, et al.
Publicado: (2019)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9t7hd772179b7bsed01vvneeot